MONDAY, OCTOBER 27TH

VIRTUAL SESSIONS ARE NOT LIVE STREAMED. THEY WILL BE RECORDED AND PUBLISHED LATER FOR VIEWING.

7:30am - 5:00pm

Registration Open

8:00am - 9:45am

PLENARY SESSION 4 - Understanding and Optimizing the Immunotherapy Response (I)

8:00am - 8:20am

PD1 and memory a smoking gun in melanoma immunotherapy and toxicity

Niroshana Anandasabapathy

8:20am - 8:35am

Heterotypic CD8 T cell clusters isolated from clinical samples are biologically distinct and enriched for antitumor activity

Johanna Veldman

8:35pm - 8:55pm

Clinical translation of new approaches in TIL therapy for metastatic melanoma

Michelle Krogsgaard

8:55pm - 9:10am

Cytotoxic NK cells impede response to checkpoint immunotherapy in melanoma with an immune-excluded phenotype

Joanna Pozniak

9:10am - 9:30am

Improving mRNA vaccines in melanoma

Inge Svane

9:30am - 9:45am

A phase II trial on precision radiation of immune checkpoint therapy resistant melanoma metastases (PROMMEL)

Hildur Helgadottir

9:45am - 9:50am

Poster Flash Talks

9:45am - 9:46am

Targeting RAS to stimulate antitumor immunity in acral melanoma cells

Geethanjali Annamalai

9:46am - 9:47am

Insights into pan-RAF targeted therapy strategies for non-BRAF V600 genotypes and as salvage for BRAF/MEK inhibitor resistant melanoma

Aristophane Chay

9:47am - 9:48am

Investigating epithelial to mesenchymal transition heterogeneity in primary and metastatic uveal melanoma samples

Catherine Van Raamsdonk

9:48am - 9:49am

Regulatory T cells inhibit CD8+ TRM-like cells during the early stages of tumor immune escape

Jason Williams

9:49am - 9:50am

Characterizing the spatial transcriptomic landscape of metastatic melanoma patients treated with combination anti-LAG-3 + anti-PD-1 immunotherapies

Tuba Gide

9:50am - 10:10am

Refreshment Break

10:10am - 11:55am

PLENARY SESSION 5 - Melanoma Microenvironment

10:10am - 10:30am

Cancer’s cradle: How malignant cells and their niche trigger tumor initiation

Lukas Sommer

10:30am - 10:45am

Sensory neurons interact directly with melanoma malignant cells and pericytes via CGRP-RAMP1 signaling to promote melanoma metastatic outgrowth

Alexander Birbrair

10:45am - 11:05am

A complex TIME: How the aging tumor immune microenvironment impacts tumor progression and response to therapy

Ashi Weeraratna

11:05am - 11:20am

Cancer acquires therapy resistance by converting immune infiltration to exclusion through NK cell-macrophage interactions.

Andrew White

11:20am - 11:40am

Melanoma control by the gut microbiome

Ze'ev Ronai

11:40am - 11:55am

A Wnt-signaled subset of tumoral macrophages promotes melanoma progression

Alexandra Thornock

11:55am - 12:00pm

Poster Flash Talks

11:55am - 11:56pm

Downregulation of polycomb repressive complex 1 ubiquitin ligases following BAP1 loss drives uveal melanoma metastasis

Emma Hammes

11:56am - 11:57pm

Investigating the combined inhibition of RAF, MEK, and FAK in melanoma molecular subtypes

Jared Almazan

11:57am - 11:58pm

DNA methylation analysis of acral melanoma identifies an independently prognostic methylation signature and type I interferon downregulation in high-risk patients

Simon Roy

11:58am - 11:59pm

Immunotherapy resistance in melanoma: From tumour-resident archetypes to targetable gene networks

Andrea Di Pietro

11:59am - 12:00pm

YAP activity predicts tumor dormancy in uveal melanoma patients: Molecular and clinicopathological insights

Nikhil Kumar

12:00pm - 1:30pm

Lunch - Exhibit & Posters

1:30pm - 3:15pm

PLENARY SESSION 6 - Rare and Challenging Melanomas

1:30pm - 1:50pm

Defining therapeutic targets in rare melanomas using genome-wide and combinatorial CRISPR screening

David Adams

1:50pm - 2:05pm

A site-specific microenvironmental program in plantar skin confers heightened metastatic capacity to acral melanomas

Vito Rebecca

2:05pm - 2:25pm

TERT activation in acral and mucosal melanoma

James Wilmott

2:25pm - 2:40pm

Efficacy and safety of IMA203, a PRAME-directed T-cell receptor (TCR) T-cell therapy, in patients with previously treated advanced or metastatic uveal melanoma from a Ph 1 trial

Kelly Blacklock

2:40pm - 3:00pm

Spatial transcriptome of immunotherapy resistant melanoma

Boris Bastian

3:00pm - 3:15pm

Canine oronasal mucosal melanoma: a companion model for drug treatment

Sapna Patel

3:15pm - 3:35pm

Refreshment Break

3:35pm - 4:20pm

Keynote Presentation

Marisol Soengas

4:20pm - 6:00pm

PLENARY SESSION 7 - Understanding and Optimizing the Immunotherapy Response (II)

Antibody-based immunotherapies for melanoma

4:20pm - 4:40pm

Rony Dahan

4:40pm - 4:55pm

Baseline gene expression profiling (GEP) stratifies recurrence risk in melanoma patients (pts) receiving neoadjuvant immunotherapy (NeoIT).

Ines Pires da Silva

4:55pm - 5:15pm

What are the limitations for melanoma cure?

Göran Jönsson

5:15pm - 5:30pm

IMA203, a PRAME-directed T-cell receptor (TCR) T-cell therapy, demonstrated broad organ penetration in patients with heavily pretreated advanced or metastatic melanoma in a phase 1 trial

Martin Wermke

5:30pm - 5:45pm

Adjuvant nivolumab plus ipilimumab in high-risk uveal melanoma: Long-term survival outcomes from HCRN MEL17-309

Suthee Rapisuwon

5:45pm - 6:05pm

Understanding the effect of ICB by mapping the ecosystem of the anti-tumor immune response in melanoma

Reinhard Dummer

7:00pm - 11:00pm

Awards Ceremony - Off Site